Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15422770 | 1.00 | ALDH1A1 (0.47) | ALDH1A1MTNR1AMTNR1BKMT2ASLC6A2 | |
| SCHEMBL6153937 | 0.83 | ALDH1A1 (0.50) | ALDH1A1HTTLMNASMN1; SMN2RAB9A | |
| SCHEMBL6153940 | 0.83 | ALDH1A1 (0.50) | ALDH1A1HTTLMNASMN1; SMN2RAB9A | |
| SCHEMBL6154638 | 0.83 | ALDH1A1 (0.50) | ALDH1A1HTTLMNASMN1; SMN2RAB9A | |
| SCHEMBL14830272 | 0.81 | MTNR1A (0.52) | ALDH1A1MTNR1AMTNR1BL3MBTL1 | |
| SCHEMBL14830271 | 0.81 | MTNR1A (0.52) | ALDH1A1MTNR1AMTNR1BL3MBTL1 | |
| SCHEMBL6153903 | 0.77 | SLC6A2 (0.53) | ALDH1A1KMT2ASLC6A2SLC6A3TDP1 | |
| SCHEMBL6153899 | 0.77 | SLC6A2 (0.53) | ALDH1A1KMT2ASLC6A2SLC6A3TDP1 | |
| SCHEMBL15422310 | 0.76 | ALDH1A1 (0.40) | ALDH1A1MTNR1AMTNR1BHTTLMNA | |
| SCHEMBL15422311 | 0.76 | ALDH1A1 (0.40) | ALDH1A1MTNR1AMTNR1BHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3095777-B1 | LINEZOLID INTERMEDIATE AND METHOD FOR SYNTHESIZING LINEZOLID | ZHEJIANG MED XINCHANG PHARM (CN) | 2018-06-27 | — | — | EP | disclosed |
| EP-3095777-A1 | LINEZOLID INTERMEDIATE AND METHOD FOR SYNTHESIZING LINEZOLID | ZheJiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory (CN) | 2016-11-23 | — | — | EP | disclosed |
| US-8962827-B2 | Linezolid intermediate and method for synthesizing linezolid | ZHEJIANG MEDICINE CO. LTD. XINCHANG PHARMACEUTICAL FACTORY (CN) | 2015-02-24 | — | — | US | disclosed |
| US-8962827-B2 | Linezolid intermediate and method for synthesizing linezolid | ZHEJIANG MEDICINE CO. LTD. XINCHANG PHARMACEUTICAL FACTORY (CN) | 2015-02-24 | — | — | US | disclosed |
| US-20140024827-A1 | LINEZOLID INTERMEDIATE AND METHOD FOR SYNTHESIZING LINEZOLID | ZHEJIANG MEDICINE CO., LTD XINCHANG PHARMACEUTICAL FACTORY (CN) | 2014-01-23 | — | — | US | disclosed |
| US-20140024827-A1 | LINEZOLID INTERMEDIATE AND METHOD FOR SYNTHESIZING LINEZOLID | ZHEJIANG MEDICINE CO., LTD XINCHANG PHARMACEUTICAL FACTORY (CN) | 2014-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024827-A1 | LINEZOLID INTERMEDIATE AND METHOD FOR SYNTHESIZING LINEZOLID | CYP2C9, CYP3A4, CYP2C19 | ALDH1A1 613/4885MTNR1A 4042/4885MTNR1B 3967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.